Skip to main content
FDMT4D Molecular Therapeutics, Inc.Sell4.8·$10.23
FDMT · Why this verdict

Why 4D Molecular Therapeutics (FDMT) is rated SELL

Updated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

VerdictSELL
Overall score4.8/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis

Engine thesis — one sentence

4D Molecular Therapeutics is a pre-revenue biotech burning cash with quality scored 2.8/10 and moderate insider selling; the case rests on 139% analyst upside from a binary clinical outcome.

Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.

Thesis pillars

The company is burning cash at -98% of revenue with a quality score of 2.8/10.

→Stable
Quality breakdown
Expectation
Cash burn narrows and quality score recovers above 4.0.

CounterCurrent ratio scores 6.8, indicating enough liquidity to fund trials for the next 12 months.

The analyst target of $24.44 implies 138.9% upside from $10.23, versus 15% downside to the stop.

↑Improving
Targets
Expectation
Price moves toward the $24.44 target as clinical milestones are reached.

CounterIn a binary biotech, one failed trial can erase the value and make the analyst target worthless.

Recent quarters show persistent small misses: 3 of the last 4 missed, with EPS near -$1.0 per quarter.

↓Deteriorating
Earnings
Expectation
Quarterly losses stay at or below $1.10 per share.

CounterThe misses are small (about 1-3%), and the March quarter beat by 181%, so losses are broadly in line with plan.

Insiders are selling $1,616,428, which is 0.280% of market cap and flagged as notable selling.

↓Deteriorating
Insider breakdown
Expectation
Insider selling fades below 0.1% of market cap.

CounterScheduled selling by biotech executives often reflects diversification, not a negative view.

Short interest is 22% with implied volatility of 214%, and momentum is weak at 2.1/10 despite a rising 200-day average.

↓Deteriorating
Risk breakdown
Expectation
Short interest falls below 15% as clinical data improves.

CounterThe 200-day average is still rising 5.6% over 30 days, so this may be a pullback in an uptrend.

Per-dimension breakdown

Value

7.9/10data confidence 33%
ComponentSub-score
P/S6.2
Analyst target9.0
  • ▸Attractively valued

Quality

2.8/10data confidence 86%
ComponentSub-score
ROE0.0
ROA0.0
Current ratio6.8
FCF quality0.0
Moat5.8
Piotroski F4.4
  • ▸Cash-burning: FCF -98% of revenue
  • ▸Quality concerns

Growth

5.0/10data confidence 50%

Momentum

2.1/10data confidence 100%
ComponentSub-score
RSI4.5
MACD1.0
OBV1.0
MA position2.2
Volume1.7
  • ▸Volume distribution (falling OBV)
  • ▸Below 200-MA but MA still rising (+5.6%/30d) — pullback in uptrend, not confirmed weakness

Sentiment

7.4/10data confidence 100%
ComponentSub-score
LLM sentiment4.0
Analyst rating8.3
Price target10.0
  • ▸Analyst upside: 175%

Insider

3.3/10data confidence 75%
ComponentSub-score
materiality3.0
insider conviction2.0
holder change5.0
  • ▸Notable insider selling — $1,616,428 (0.280% of mkt cap)

Peer rank

5.3/10data confidence 80%
ComponentSub-score
value rank6.1
quality rank1.0
growth rank10.0
  • ▸Industry growth leader

Technical

7.1/10data confidence 100%
ComponentSub-score
bollinger9.7
support resistance9.6
52w position2.1
gap7.0

Risk (lower is worse)

3.0/10data confidence 100%
ComponentSub-score
short interest1.3
days to cover0.0
volatility0.0
put call10.0
implied vol0.0
beta0.3
debt equity9.5
  • ▸High short interest justified: 22%
  • ▸High IV: 206%

Catalyst

3.3/10data confidence 100%
ComponentSub-score
erm5.0
earnings history0.0
earnings timing5.0
surprise avg1.4
news activity5.0
  • ▸Earnings concerns: 0B/3M

How the verdict was assembled

Engine trigger

Quality below minimum threshold.

Engine technical detail
verdict_path: L1:HARD_BLOCK:QUALITY_FLOOR
Passed (6)
  • ASYMMETRY:9.3>=1.5
  • 8K:CLEAN
  • NEWS_EVENTS:NONE_RECENT
  • EARNINGS_PROXIMITY:115d clear
  • SEMI_CYCLE_PEAK:CLEAR
  • MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
  • MOMENTUM:2.1<4.5
Warning (1)
  • INSIDER:0.28%=MODERATE
Reward-to-Risk
9.26
Upside
+138.9%
Downside
15.0%
Sizing output
AVOID

Setup— — No clear chart pattern; technical signals are mixed

EdgeInst Constrain — Small cap ($0.6B) below institutional reach

SuitabilitySpeculative — Binary industry: Biotechnology

Investment implication

The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 2.1<4.5 outcome against Value at 7.9 and asymmetric R:R of 9.26.

The strongest dimensions are Value at 7.9, Sentiment at 7.4, and Technical at 7.1; the weakest are Momentum at 2.1, Quality at 2.8, and Risk (lower is worse) at 3.0. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 9.26 and an engine sizing output of AVOID.

What would invalidate the thesis

Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.

  • P1Heavy Cash Burn

    Trip ifQuality score stays below 2.5 from current 2.8 for 2 consecutive quarters.

  • P2Analyst Target Upside

    Trip ifAnalyst target falls below $15 from $24.44.

  • P3Persistent Eps Misses

    Trip ifQuarterly EPS loss exceeds $1.25 per share.

  • P4Insider Selling Signal

    Trip ifInsider selling exceeds 0.5% of market cap over 90 days.

  • P5High Short Interest Volatility

    Trip ifShare price falls below the $9.81 stop level, more than 4% below $10.23.

Engine reasoning is mechanically derived from pipeline gate outputs. See decision view.

Home › Stocks › FDMT › Why this verdict